<DOC>
	<DOCNO>NCT01047839</DOCNO>
	<brief_summary>The primary objective ass safety profile IC51 pediatric population region JEV endemic</brief_summary>
	<brief_title>Immunogenicity Safety Japanese Encephalitis Vaccine IC51 ( IXIARO® , JESPECT® ) Pediatric Population Non-endemic Countries</brief_title>
	<detailed_description />
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Encephalitis , Japanese</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female healthy child adolescent age &gt; =2 month &lt; 18 year time first vaccination Written inform consent subject 's legal representative ( ) , accord local requirement , write informed assent subject , applicable Female subject : either childbearing potential negative pregnancy test . For female menarche willingness practice reliable method contraception . The subject planning travel area JE endemic completion vaccination schedule . Exposure JE avoid 1 week second IC51 dose subject return travel JE endemic area Month 7 visit . The plan travel JE endemic area interfere study visit take place Visit 2 + 7 day Month 7 . Clinical manifestation history Flavivirus disease Vaccination JE ( except within protocol ) , Yellow fever , West Nile virus Dengue time prior study History immunodeficiency immunosuppressive therapy Known HIV , HBV HCV infection History hypersensitivity reaction vaccine Acute febrile infection visit subject receive vaccination Active passive immunization within 1 week 1 week IC51 vaccination .</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Pediatric</keyword>
	<keyword>Japanese Encephalitis Vaccine</keyword>
	<keyword>non-endemic country</keyword>
	<keyword>assess immunogenicity purify inactivated Japanese Encephalitis ( JE ) vaccine IC51</keyword>
</DOC>